Home » Stocks » CERE

Cerevel Therapeutics Holdings, Inc. (CERE)

Stock Price: $13.60 USD 0.28 (2.10%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $13.20 -0.40 (-2.94%) May 14, 4:30 PM
Market Cap 1.73B
Revenue (ttm) n/a
Net Income (ttm) -148.27M
Shares Out 127.44M
EPS (ttm) -2.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $13.60
Previous Close $13.32
Change ($) 0.28
Change (%) 2.10%
Day's Open 13.46
Day's Range 13.19 - 13.95
Day's Volume 201,092
52-Week Range 9.00 - 18.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it...

2 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of...

3 weeks ago - GlobeNewsWire

Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson's disease through planned NDA submission

1 month ago - GlobeNewsWire

Data readout of Phase 1b trial of CVL-231 in patients with schizophrenia now expected mid-year 2021

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that Chai...

1 month ago - GlobeNewsWire

Darigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric Modulator

3 months ago - GlobeNewsWire

Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will ho...

5 months ago - GlobeNewsWire

About CERE

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a se... [Read more...]

Industry
Biotechnology
Founded
2018
Stock Exchange
NASDAQ
Ticker Symbol
CERE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for CERE is 22.00, which is an increase of 61.76% from the latest price.

Price Target
$22.00
(61.76% upside)